Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
- Development stage
- Phase 3
- Lead developer
- Takeda
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This vaccine is a live, attenuated, recombinant formulation designed to protect against dengue fever caused by all four serotypes of the dengue virus (serotypes 1, 2, 3, and 4). It works by introducing weakened, genetically modified versions of the virus to stimulate the immune system to produce neutralizing antibodies, thereby conferring immunity.
- Other names
- Tetravalent Dengue Vaccine
Beyond the preview
Go deeper on live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus.